Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data Monitoring Committee (DMC) has recommended Celgene International to discontinue its Phase III Mainsail trial.
Subscribe to our email newsletter
The pivotal double-blinded trial was designed to assess the safety and efficacy of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prosta te cancer (CRPC).
The company decided to discontinue the trial based upon the findings that the combination of docetaxel and prednisone plus lenalidomide would not demonstrate a statistically significant treatment effect against the primary endpoint of overall survival versus docetaxel and prednisone plus placebo.